Osteogenesis Imperfecta

Osteogenesis Imperfecta: Pathophysiology and Clinical Presentation of Brittle

Bone Disease

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a rare inherited

connective tissue disorder characterized by fragile bones that fracture easily, often from little

or no apparent cause. Beyond fragility though, OI also involves abnormalities in other

connective tissues such as sclera, dentin, ligaments and skin. It represents a heterogeneous

group of conditions arising from defects in collagen biosynthesis leading to qualitatively or

quantitatively insufficient type I collagen, the major collagen protein involved in bone

formation. The severity ranges widely from mild to lethal congenital forms producing

OI results from mutations in one of two genes- COL1A1 or COL1A2 encoding alpha-1 and

alpha-2 chains of type I procollagen respectively, which combine to form type I collagen

triple helices integral to bone, ligament and vascular structures. Over 1800 mutations have

been reported affecting transcription, translation or post-translational processing causing

either quantitative collagen deficiency or production of structurally abnormal collagen

molecules. These defects impair collagen triple helix formation and subsequent extracellular

fiber assembly compromising tissue integrity and strength, triggering aberrant bone formation

and increased fragility.

The two main genetic subtypes are:

1. OI types I-IV caused by dominant new mutations in either COL1A1 or COL1A2 genes in

diagnosis through identification of causative mutations is possible for families with history.

Clinical Features and Classification

OI displays a wide phenotypic spectrum depending upon the underlying genetic defect from

mostly asymptomatic cases to extremely lethal perinatal forms. Sillence et al proposed a

classification system dividing OI into four main types described below:

Type I (Mild): Most common variety affecting 1/15,000. Characterized by bone fragility with

blue sclera and few other manifestations. Fractures heal normally. Life expectancy is normal.

Type II (Perinatal lethal): Rare severe form evident at birth with gracile bones, respiratory

insufficiency and fatal fractures. Lethal in utero or perinatally.

Type III (Progressive deforming): Moderate to severe form with recurrent fractures,

findings:

- Type V (OI with calcification of interosseous membranes)

- Type VI (OI with hyphal fibrosis)

- Type VII (CRTAP-related recessive OI)

- Type VIII (LEPRE1-related recessive OI)

- Type IX (IFITM5-related dominant OI with normal sclerae)

- Type X-XIII (Rarer recessive forms)

Diagnosis

Diagnosis begins with clinical assessment noting the characteristic bone fragility and frequent

fractures from minimal or no trauma. Radiographs demonstrate abnormal bone structure

- Pathological diagnosis through iliac crest bone biopsy helps delineate subtype

- Prenatal ultrasound reveals characteristic skeletal abnormalities if suspected during

pregnancy

Differential diagnoses include other inherited disorders with skeletal fragility like

osteoporosis pseudoglioma syndrome or more common acquired osteoporosis. A

multidisciplinary approach integrating clinical, radiological, collagen/genetic assessments

establishes a definitive diagnosis and classification.

Management

Management follows a multimodal approach tailored to the OI type and involves

coordination between orthopedics, physiatry, dentistry, ophthalmology and genetic

counseling specialists.

Bisphosphonates: Improve bone density and strength significantly reducing incident fractures

by inhibiting osteoclast bone resorption. Pamidronate and zoledronic acid intravenous

Physical/Occupational Therapy: Strengthen muscles, improve mobility, maintain range of

posture. Selective surgical straightening of limbs may be done.

Monitoring & Prevention: Strict fall precautions, padding playgrounds, wheelchairs for

ambulation help prevent fractures. Annual ophthalmic screening, hearing checks for

deforming types. Dental care ensures healthy occlusion.

Genetic Counseling: Carrier detection, prenatal diagnosis through collagen/DNA studies aids

reproduction decisions for affected families. Prenatal bisphosphonates show promise in lethal

Rehabilitation: Physical rehabilitation with assistive devices improves mobility and

independence with activities of daily living. Psychological support aids coping and self-care

Prognosis

With improved diagnosis and management including bisphosphonate therapy, today the

overall 10-year survival rates exceed 95% even in moderate to severe OI. Milder types have a

Deforming subtypes have average lifespans into the 6th or 7th decade but with comorbidities

from bone deformities, hearing loss, pulmonary issues or kyphoscoliosis. Severe subtypes

deformities lead to mobility restrictions.

Perinatal lethal OI nearly always leads to in-utero demise or early postnatal death. Recent

advancements with prenatal bisphosphonates or emergency rod fixation in newborns have

helped a few survive infancy albeit with severe physical limitations. Early initiation and strict

lifelong adherence to multidisciplinary medical and rehabilitative care remains the mainstay

optimizing long term prognosis in osteogenesis imperfecta.

In summary, osteogenesis imperfecta covers a wide phenotypic spectrum representing a

Continuous research aims to elucidate novel molecular targets aiding development of disease

modifying or curative therapies and provide a brighter future for this challenging condition

presenting with fragile bones from birth.

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a rare inherited

connective tissue disorder characterized by fragile bones that fracture easily, often from little

or no apparent cause. Beyond fragility though, OI also involves abnormalities in other

group of conditions arising from defects in collagen biosynthesis leading to qualitatively or

quantitatively insufficient type I collagen, the major collagen protein involved in bone

formation. The severity ranges widely from mild to lethal congenital forms producing

alpha-2 chains of type I procollagen respectively, which combine to form type I collagen

triple helices integral to bone, ligament and vascular structures. Over 1800 mutations have

been reported affecting transcription, translation or post-translational processing causing

molecules. These defects impair collagen triple helix formation and subsequent extracellular

fiber assembly compromising tissue integrity and strength, triggering aberrant bone formation

and increased fragility.

1. OI types I-IV caused by dominant new mutations in either COL1A1 or COL1A2 genes in

90% cases presenting with variable clinical severity. Heterozygous mutations lead to

structurally normal yet insufficient collagen.

2. OI types VII and VIII- recessive forms associated with biallelic mutations in COL1A1 or

COL1A2 genes respectively producing structurally abnormal collagen.

synthesis or structure like CRTAP, LEPRE1, PPIB, SERPINH1 and FKBP10. Prenatal

classification system dividing OI into four main types described below:

Type I (Mild): Most common variety affecting 1/15,000. Characterized by bone fragility with

blue sclera and few other manifestations. Fractures heal normally. Life expectancy is normal.

Type II (Perinatal lethal): Rare severe form evident at birth with gracile bones, respiratory

insufficiency and fatal fractures. Lethal in utero or perinatally.

progressive deformity of long bones leading to short stature and scoliosis. Hearing loss may

occur. Average lifespan shortened.

- Type VI (OI with hyphal fibrosis)

- Type VII (CRTAP-related recessive OI)

- Type VIII (LEPRE1-related recessive OI)

- Type X-XIII (Rarer recessive forms)

Diagnosis

fractures from minimal or no trauma. Radiographs demonstrate abnormal bone structure

appearing thin, gracile, osteopenic and dotted with zones of provisional calcification (callus

formation) at fracture sites suggestive of impaired healing.

Additional confirmatory tests include:

- Biochemical collagen analysis detecting reduced collagen synthesis/secretion

- Pathological diagnosis through iliac crest bone biopsy helps delineate subtype

multidisciplinary approach integrating clinical, radiological, collagen/genetic assessments

establishes a definitive diagnosis and classification.

Management

Management follows a multimodal approach tailored to the OI type and involves

coordination between orthopedics, physiatry, dentistry, ophthalmology and genetic

counseling specialists.

by inhibiting osteoclast bone resorption. Pamidronate and zoledronic acid intravenous

regimens demonstrate efficacy in moderate to severe OI subtypes.

Monitoring & Prevention: Strict fall precautions, padding playgrounds, wheelchairs for

ambulation help prevent fractures. Annual ophthalmic screening, hearing checks for

deforming types. Dental care ensures healthy occlusion.

Genetic Counseling: Carrier detection, prenatal diagnosis through collagen/DNA studies aids

reproduction decisions for affected families. Prenatal bisphosphonates show promise in lethal

perinatal forms.

independence with activities of daily living. Psychological support aids coping and self-care

learning.

Strict adherence to multidisciplinary care throughout life along with genetic advances and

emerging therapeutic targets may significantly improve morbidity and quality of life,

transforming previously mortal conditions like severe OI into lifelong chronic but

manageable disorders. Education and community support programs aid this rare disease

Prognosis

from bone deformities, hearing loss, pulmonary issues or kyphoscoliosis. Severe subtypes

have reduced survival averaging between 30 to 50 years. Extensive spinal or long bone

deformities lead to mobility restrictions.

Perinatal lethal OI nearly always leads to in-utero demise or early postnatal death. Recent

advancements with prenatal bisphosphonates or emergency rod fixation in newborns have

helped a few survive infancy albeit with severe physical limitations. Early initiation and strict

lifelong adherence to multidisciplinary medical and rehabilitative care remains the mainstay

Conclusion

In summary, osteogenesis imperfecta covers a wide phenotypic spectrum representing a

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a rare inherited

connective tissue disorder characterized by fragile bones that fracture easily, often from little

connective tissues such as sclera, dentin, ligaments and skin. It represents a heterogeneous

group of conditions arising from defects in collagen biosynthesis leading to qualitatively or

quantitatively insufficient type I collagen, the major collagen protein involved in bone

formation. The severity ranges widely from mild to lethal congenital forms producing

along with improvements in medical, surgical and rehabilitation approaches have enhanced

our understanding and management of OI over recent decades. This comprehensive review

covers the current knowledge on pathophysiology, clinical features, classification, diagnostic

criteria and multidisciplinary care principles for osteogenesis imperfecta.

Pathophysiology and Genetics

OI results from mutations in one of two genes- COL1A1 or COL1A2 encoding alpha-1 and

been reported affecting transcription, translation or post-translational processing causing

The two main genetic subtypes are:

1. OI types I-IV caused by dominant new mutations in either COL1A1 or COL1A2 genes in

90% cases presenting with variable clinical severity. Heterozygous mutations lead to

structurally normal yet insufficient collagen.

2. OI types VII and VIII- recessive forms associated with biallelic mutations in COL1A1 or

COL1A2 genes respectively producing structurally abnormal collagen.

A few rarer recessive forms involve defects in other genes important for procollagen

synthesis or structure like CRTAP, LEPRE1, PPIB, SERPINH1 and FKBP10. Prenatal

diagnosis through identification of causative mutations is possible for families with history.

Type II (Perinatal lethal): Rare severe form evident at birth with gracile bones, respiratory

insufficiency and fatal fractures. Lethal in utero or perinatally.

Type III (Progressive deforming): Moderate to severe form with recurrent fractures,

progressive deformity of long bones leading to short stature and scoliosis. Hearing loss may

occur. Average lifespan shortened.

more marked than type I. Stature usually normal and no tendency for progressive deformity

as in type III.

Beyond these, other variants include types V-XIII based on additional clinical or genetic

findings:

- Type V (OI with calcification of interosseous membranes)

- Type VIII (LEPRE1-related recessive OI)

fractures from minimal or no trauma. Radiographs demonstrate abnormal bone structure

appearing thin, gracile, osteopenic and dotted with zones of provisional calcification (callus

formation) at fracture sites suggestive of impaired healing.

Additional confirmatory tests include:

- Biochemical collagen analysis detecting reduced collagen synthesis/secretion

- Molecular genetic testing of COL1A1/COL1A2 for mutations

- Pathological diagnosis through iliac crest bone biopsy helps delineate subtype

- Prenatal ultrasound reveals characteristic skeletal abnormalities if suspected during

pregnancy

coordination between orthopedics, physiatry, dentistry, ophthalmology and genetic

counseling specialists.

by inhibiting osteoclast bone resorption. Pamidronate and zoledronic acid intravenous

regimens demonstrate efficacy in moderate to severe OI subtypes.

- Type IX (IFITM5-related dominant OI with normal sclerae)

- Type X-XIII (Rarer recessive forms)

Diagnosis

Diagnosis begins with clinical assessment noting the characteristic bone fragility and frequent

fractures from minimal or no trauma. Radiographs demonstrate abnormal bone structure

appearing thin, gracile, osteopenic and dotted with zones of provisional calcification (callus

Additional confirmatory tests include:

- Prenatal ultrasound reveals characteristic skeletal abnormalities if suspected during

pregnancy

Differential diagnoses include other inherited disorders with skeletal fragility like

osteoporosis pseudoglioma syndrome or more common acquired osteoporosis. A

multidisciplinary approach integrating clinical, radiological, collagen/genetic assessments

establishes a definitive diagnosis and classification.

Management follows a multimodal approach tailored to the OI type and involves

coordination between orthopedics, physiatry, dentistry, ophthalmology and genetic

counseling specialists.

Surgery: Frequent fractures may require fixation with intramedullary rods or plates. Scoliosis

surgery using growing rods in young children or spinal fusion when mature helps maintain

Monitoring & Prevention: Strict fall precautions, padding playgrounds, wheelchairs for

ambulation help prevent fractures. Annual ophthalmic screening, hearing checks for

deforming types. Dental care ensures healthy occlusion.

Genetic Counseling: Carrier detection, prenatal diagnosis through collagen/DNA studies aids

reproduction decisions for affected families. Prenatal bisphosphonates show promise in lethal

perinatal forms.

Rehabilitation: Physical rehabilitation with assistive devices improves mobility and

independence with activities of daily living. Psychological support aids coping and self-care

learning.

emerging therapeutic targets may significantly improve morbidity and quality of life,

With improved diagnosis and management including bisphosphonate therapy, today the

overall 10-year survival rates exceed 95% even in moderate to severe OI. Milder types have a

normal lifespan and only sustain occasional fractures without long term implications.

Deforming subtypes have average lifespans into the 6th or 7th decade but with comorbidities

from bone deformities, hearing loss, pulmonary issues or kyphoscoliosis. Severe subtypes

have reduced survival averaging between 30 to 50 years. Extensive spinal or long bone

deformities lead to mobility restrictions.

Perinatal lethal OI nearly always leads to in-utero demise or early postnatal death. Recent

advancements with prenatal bisphosphonates or emergency rod fixation in newborns have

helped a few survive infancy albeit with severe physical limitations. Early initiation and strict

coordinated clinical management have improved diagnostic accuracy, enabled prenatal

testing and vastly enhanced long term survival and quality of life most affected individuals.

Continuous research aims to elucidate novel molecular targets aiding development of disease

presenting with fragile bones from birth.

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a rare inherited

connective tissue disorder characterized by fragile bones that fracture easily, often from little

connective tissues such as sclera, dentin, ligaments and skin. It represents a heterogeneous

group of conditions arising from defects in collagen biosynthesis leading to qualitatively or

quantitatively insufficient type I collagen, the major collagen protein involved in bone

formation. The severity ranges widely from mild to lethal congenital forms producing

variability in presentation and natural history. Advances in genetic and molecular diagnosis

along with improvements in medical, surgical and rehabilitation approaches have enhanced

our understanding and management of OI over recent decades. This comprehensive review

either quantitative collagen deficiency or production of structurally abnormal collagen

molecules. These defects impair collagen triple helix formation and subsequent extracellular

fiber assembly compromising tissue integrity and strength, triggering aberrant bone formation

and increased fragility.

The two main genetic subtypes are:

1. OI types I-IV caused by dominant new mutations in either COL1A1 or COL1A2 genes in

structurally normal yet insufficient collagen.

2. OI types VII and VIII- recessive forms associated with biallelic mutations in COL1A1 or

mostly asymptomatic cases to extremely lethal perinatal forms. Sillence et al proposed a

classification system dividing OI into four main types described below:

blue sclera and few other manifestations. Fractures heal normally. Life expectancy is normal.

Type II (Perinatal lethal): Rare severe form evident at birth with gracile bones, respiratory

insufficiency and fatal fractures. Lethal in utero or perinatally.

Type III (Progressive deforming): Moderate to severe form with recurrent fractures,

progressive deformity of long bones leading to short stature and scoliosis. Hearing loss may

occur. Average lifespan shortened.

Type IV (Moderate non-deforming): Intermediate in severity with fractures and scleral hue

more marked than type I. Stature usually normal and no tendency for progressive deformity

as in type III.

findings:

- Type IX (IFITM5-related dominant OI with normal sclerae)

- Type X-XIII (Rarer recessive forms)

Diagnosis

Diagnosis begins with clinical assessment noting the characteristic bone fragility and frequent

fractures from minimal or no trauma. Radiographs demonstrate abnormal bone structure

appearing thin, gracile, osteopenic and dotted with zones of provisional calcification (callus

formation) at fracture sites suggestive of impaired healing.

Additional confirmatory tests include:

- Biochemical collagen analysis detecting reduced collagen synthesis/secretion

multidisciplinary approach integrating clinical, radiological, collagen/genetic assessments

establishes a definitive diagnosis and classification.

Management follows a multimodal approach tailored to the OI type and involves

coordination between orthopedics, physiatry, dentistry, ophthalmology and genetic

counseling specialists.

by inhibiting osteoclast bone resorption. Pamidronate and zoledronic acid intravenous

regimens demonstrate efficacy in moderate to severe OI subtypes.

Physical/Occupational Therapy: Strengthen muscles, improve mobility, maintain range of

joint motion and prevent contractures through specific gentle exercises and supportive

devices. Braces and splints aid fracture healing.

posture. Selective surgical straightening of limbs may be done.

Genetic Counseling: Carrier detection, prenatal diagnosis through collagen/DNA studies aids

reproduction decisions for affected families. Prenatal bisphosphonates show promise in lethal

perinatal forms.

Rehabilitation: Physical rehabilitation with assistive devices improves mobility and

independence with activities of daily living. Psychological support aids coping and self-care

learning.

emerging therapeutic targets may significantly improve morbidity and quality of life,

transforming previously mortal conditions like severe OI into lifelong chronic but

manageable disorders. Education and community support programs aid this rare disease

from bone deformities, hearing loss, pulmonary issues or kyphoscoliosis. Severe subtypes

have reduced survival averaging between 30 to 50 years. Extensive spinal or long bone

deformities lead to mobility restrictions.

Perinatal lethal OI nearly always leads to in-utero demise or early postnatal death. Recent

advancements with prenatal bisphosphonates or emergency rod fixation in newborns have

helped a few survive infancy albeit with severe physical limitations. Early initiation and strict

optimizing long term prognosis in osteogenesis imperfecta.

Conclusion

In summary, osteogenesis imperfecta covers a wide phenotypic spectrum representing a

group of heritable disorders of collagen caused by pathogenic mutations affecting type I

collagen synthesis. The hallmark is increased bone fragility along with extra-skeletal features

depending on the subtype. Advancements in genetic understanding and multisystem

Continuous research aims to elucidate novel molecular targets aiding development of disease

or no apparent cause. Beyond fragility though, OI also involves abnormalities in other

connective tissues such as sclera, dentin, ligaments and skin. It represents a heterogeneous

group of conditions arising from defects in collagen biosynthesis leading to qualitatively or

quantitatively insufficient type I collagen, the major collagen protein involved in bone

formation. The severity ranges widely from mild to lethal congenital forms producing

variability in presentation and natural history. Advances in genetic and molecular diagnosis

along with improvements in medical, surgical and rehabilitation approaches have enhanced

our understanding and management of OI over recent decades. This comprehensive review

criteria and multidisciplinary care principles for osteogenesis imperfecta.

Pathophysiology and Genetics

The two main genetic subtypes are:

90% cases presenting with variable clinical severity. Heterozygous mutations lead to

structurally normal yet insufficient collagen.

COL1A2 genes respectively producing structurally abnormal collagen.

A few rarer recessive forms involve defects in other genes important for procollagen

synthesis or structure like CRTAP, LEPRE1, PPIB, SERPINH1 and FKBP10. Prenatal

diagnosis through identification of causative mutations is possible for families with history.

Clinical Features and Classification

classification system dividing OI into four main types described below:

insufficiency and fatal fractures. Lethal in utero or perinatally.

Type III (Progressive deforming): Moderate to severe form with recurrent fractures,

progressive deformity of long bones leading to short stature and scoliosis. Hearing loss may

occur. Average lifespan shortened.

Type IV (Moderate non-deforming): Intermediate in severity with fractures and scleral hue

more marked than type I. Stature usually normal and no tendency for progressive deformity

Beyond these, other variants include types V-XIII based on additional clinical or genetic

findings:

Diagnosis

Diagnosis begins with clinical assessment noting the characteristic bone fragility and frequent

fractures from minimal or no trauma. Radiographs demonstrate abnormal bone structure

formation) at fracture sites suggestive of impaired healing.

Additional confirmatory tests include:

- Molecular genetic testing of COL1A1/COL1A2 for mutations

- Scleral hue assessment through ophthalmoscopic and Wood's lamp examination

- Pathological diagnosis through iliac crest bone biopsy helps delineate subtype

- Prenatal ultrasound reveals characteristic skeletal abnormalities if suspected during

pregnancy

Differential diagnoses include other inherited disorders with skeletal fragility like

establishes a definitive diagnosis and classification.

Bisphosphonates: Improve bone density and strength significantly reducing incident fractures

by inhibiting osteoclast bone resorption. Pamidronate and zoledronic acid intravenous

regimens demonstrate efficacy in moderate to severe OI subtypes.

Physical/Occupational Therapy: Strengthen muscles, improve mobility, maintain range of

joint motion and prevent contractures through specific gentle exercises and supportive

devices. Braces and splints aid fracture healing.

Surgery: Frequent fractures may require fixation with intramedullary rods or plates. Scoliosis

surgery using growing rods in young children or spinal fusion when mature helps maintain

posture. Selective surgical straightening of limbs may be done.

Rehabilitation: Physical rehabilitation with assistive devices improves mobility and

independence with activities of daily living. Psychological support aids coping and self-care

Strict adherence to multidisciplinary care throughout life along with genetic advances and

emerging therapeutic targets may significantly improve morbidity and quality of life,

transforming previously mortal conditions like severe OI into lifelong chronic but

population.

Prognosis

With improved diagnosis and management including bisphosphonate therapy, today the

overall 10-year survival rates exceed 95% even in moderate to severe OI. Milder types have a

normal lifespan and only sustain occasional fractures without long term implications.

have reduced survival averaging between 30 to 50 years. Extensive spinal or long bone

lifelong adherence to multidisciplinary medical and rehabilitative care remains the mainstay

optimizing long term prognosis in osteogenesis imperfecta.

Conclusion

In summary, osteogenesis imperfecta covers a wide phenotypic spectrum representing a

group of heritable disorders of collagen caused by pathogenic mutations affecting type I

collagen synthesis. The hallmark is increased bone fragility along with extra-skeletal features

depending on the subtype. Advancements in genetic understanding and multisystem

testing and vastly enhanced long term survival and quality of life most affected individuals.

Continuous research aims to elucidate novel molecular targets aiding development of disease

modifying or curative therapies and provide a brighter future for this challenging condition

formation. The severity ranges widely from mild to lethal congenital forms producing

variability in presentation and natural history. Advances in genetic and molecular diagnosis

along with improvements in medical, surgical and rehabilitation approaches have enhanced

covers the current knowledge on pathophysiology, clinical features, classification, diagnostic

criteria and multidisciplinary care principles for osteogenesis imperfecta.

Pathophysiology and Genetics

alpha-2 chains of type I procollagen respectively, which combine to form type I collagen

triple helices integral to bone, ligament and vascular structures. Over 1800 mutations have

been reported affecting transcription, translation or post-translational processing causing

either quantitative collagen deficiency or production of structurally abnormal collagen

molecules. These defects impair collagen triple helix formation and subsequent extracellular

fiber assembly compromising tissue integrity and strength, triggering aberrant bone formation

and increased fragility.

COL1A2 genes respectively producing structurally abnormal collagen.

A few rarer recessive forms involve defects in other genes important for procollagen

synthesis or structure like CRTAP, LEPRE1, PPIB, SERPINH1 and FKBP10. Prenatal

diagnosis through identification of causative mutations is possible for families with history.

Clinical Features and Classification

OI displays a wide phenotypic spectrum depending upon the underlying genetic defect from

classification system dividing OI into four main types described below:

Type I (Mild): Most common variety affecting 1/15,000. Characterized by bone fragility with

Type IV (Moderate non-deforming): Intermediate in severity with fractures and scleral hue

more marked than type I. Stature usually normal and no tendency for progressive deformity

Beyond these, other variants include types V-XIII based on additional clinical or genetic

findings: